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AbstrACt
Objectives Prolonged grief disorder is associated with 
significant distress and impairment and thus efforts to 
improve treatments are essential. The present pilot study 
tested the efficacy and feasibility of group Metacognitive 
Grief Therapy (MCGT) designed specifically for prolonged 
grief symptomatology to reduce the psychological distress 
and impaired function resulting from bereavement.
Design/participants Twenty-two bereaved adult participants 
with prolonged grief symptomatology were randomised to a 
wait-list control (n=10) or an intervention condition (n=12) 
with a 3-month and 6-month follow-up. The wait-list control 
group was offered treatment after the post-test assessment.
Intervention Participants attended six group MCGT 
sessions that ran for 2 hours per week.
Outcome measures A primary outcome measure 
of prolonged grief symptomatology and secondary 
outcome measures of depression, anxiety, rumination, 
metacognitive beliefs and quality of life were taken 
pretreatment and post-treatment for both groups and at 
the 3-month and 6-month follow-up for the intervention 
group. A Generalised Linear Mixed Model was used to 
assess treatment efficacy.
results Post-treatment intent-to-treat analyses showed 
MCGT reduced prolonged grief symptomatology (Cohen’s 
d=1.7), depression (d=1.3), anxiety (d=0.8), stress 
(d=1.0), rumination (d=0.9) and increased quality of life 
(d=0.6), and these effects were maintained at the 3-month 
and 6-month follow-ups. No prepost between-group 
differences were found in metacognitive beliefs. However, 
a large significant effect was identified at the 3-month and 
6-month follow-ups (d=1.0).
Conclusion The results show promise for the utility 
of group MCGT for reducing psychological distress 
and promoting quality of life. Additionally, the results 
underscore the need for a full randomised controlled trial 
of group MCGT, which may be an important addition to the 
treatment armamentarium available to support people with 
prolonged grief.
trial registration number ACTRN12613001270707; 
Results.
Original protocol BMJ Open 2015;5:e007221. 
doi:10.1136/bmjopen-2014-007221
IntrODuCtIOn 
Prolonged grief disorder (PGD) is a 
debilitating condition experienced by 
approximately 7% of the bereaved popula-
tion.1 2 Those experiencing PGD find it diffi-
cult to come to terms with the loss, lose their 
sense of purpose in life, avoid reminders of 
the loss, become preoccupied with thoughts 
of the deceased and experience an intense 
yearning for the deceased that does not remit 
with time.3 4 This intense distress is associated 
with social and occupational impairment and 
high levels of self-neglect (eg, self-care and 
nutrition), health issues and substance use.5
Bereaved people have often been diagnosed 
with major depression or post-traumatic 
stress disorder following a traumatic death.6 
However, factor analytic studies have estab-
lished PGD symptomatology is distinct from 
anxiety and depression and independently 
associated with considerable morbidity 
and increased suicidality.4 5 Encouragingly, 
the recent inclusion of persistent complex 
bereavement disorder in the fifth edition 
of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5)7 and the inclusion 
of PGD in the next International Classifica-
tion of Diseases (ICD)8 means more people 
experiencing prolonged symptoms with grief 
will be identified. However, current effec-
tive evidence-based therapies for PGD are 
limited.4 9 PGD is known to persist without 
adequate treatment,10 thus treatments 
strengths and limitations of this study
 ► Metacognitive Grief Therapy was found to be a short 
and effective treatment for prolonged grief with low 
attrition.
 ► The effect sizes achieved by the six session 
Metacognitive Grief Therapy programme were large 
and it was well received by bereaved people, provid-
ing support for the utility of the programme for peo-
ple experiencing prolonged grief symptomatology.
 ► The small sample size and no comparative treat-
ment underscore the need for a larger randomised 
controlled trial of Metacognitive Grief Therapy.
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specifically for PGD to ameliorate the loss of functioning 
and psychosocial distress resulting from bereavement are 
needed, and research is required to test the efficacy of 
these interventions.
Emerging evidence supports the use of psychoso-
cial interventions designed to target PGD directly 
using components of cognitive behavioural therapy.4 
For example, a pioneer study by Shear et al11 trialled a 
20-session treatment comprising exposure therapy, inter-
personal therapy and motivational interviewing specif-
ically designed for complicated grief, and a 12-session 
intervention comprising six sessions of cognitive restruc-
turing and six sessions of exposure,12 both demon-
strated significant reductions in PGD symptomatology. 
Furthermore, comparative studies trialling exposure 
therapy against cognitive restructuring and behavioural 
activation12 13 found exposure therapy produces greater 
reductions in PGD than behavioural activation or cogni-
tive restructuring. However, several individual sessions of 
exposure therapy are required11 14–16 during treatment 
due to the uniqueness of each person’s death story and, 
as such, it may not be feasible for services that can only 
offer support groups or a limited number of sessions. 
Thus far, group interventions for PGD have not produced 
the effect sizes achieved by individual interventions and 
have experienced substantial attrition.14–18
The above studies support the use of therapeutic inter-
ventions for PGD, but raise questions about what more 
could be done to tailor interventions to target the mech-
anisms underlying PGD directly. Unlike other psycho-
logical disorders, such as depression and anxiety, PGD 
involves mental anguish over many realistic thoughts 
about the events surrounding the death and the conse-
quences of the loss (eg, shock the deceased will not be 
returning, financial stressors), rather than maladap-
tive thoughts about perceived threat.19 Research has 
identified excessive worry about the uncertainty of the 
future and repetitive thinking about the events and 
emotions related to the loss both intensify PGD symptom-
atology.20–23 Recent research has demonstrated that the 
use of rumination as a coping process may be associated 
with poor bereavement outcomes24 with a growing body 
of literature suggesting that rumination may be used as 
an anxious avoidant coping process by the bereaved as 
a means to avoid the reality of the loss.25 26 Therefore, a 
treatment for PGD that addresses the maladaptive coping 
processes used to manage loss-related thoughts may be 
more effective than addressing the content of maladap-
tive thoughts.
Within the large family of cognitive behavioural ther-
apies are contemporary approaches that do not empha-
sise modification of the content of thoughts. One such 
approach is metacognitive therapy (MCT), underpinned 
by the metacognitive model of psychological disorder, 
which is framed within a general self-regulatory executive 
function model.27 The central premise of the metacogni-
tive model is that psychological disorders arise not from 
negative or dysfunctional thoughts per se but rather from 
the way individuals respond to such thoughts. Psycholog-
ical disorders are associated with the cognitive attentional 
syndrome (CAS),27 a particular style of thinking and 
responding to thoughts and/or feelings.
The CAS involves chains of worry/rumination, threat 
monitoring and maladaptive coping behaviours (eg, 
thought suppression and avoidance behaviours) and is 
driven by positive and negative metacognitive beliefs. For 
example, a traumatic memory may be responded to with 
rumination, driven by the metacognitive belief that rumi-
nation is necessary to find answers to what happened. 
This way of responding maintains threat monitoring 
and prevents adaptive emotional processing.28 MCT 
aims to interrupt the CAS to enable adaptive emotional 
processing to occur and to modify unhelpful metacogni-
tive beliefs. MCT focuses on modifying unhelpful thought 
processes such as rumination and worry. Various ther-
apeutic techniques are used in MCT, such as detached 
mindfulness, attention training technique (ATT) and 
behavioural experiments.29
As MCT focuses on unhelpful thought processes that 
maintain psychological disorders, we felt that it may offer 
great promise in the treatment of PGD. To investigate 
this further, we recently conducted a qualitative study 
of the metacognitive beliefs occurring in the context 
of PGD.30 A number of metacognitive beliefs were 
maintaining rumination, worry and avoidance coping 
behaviours. For instance, bereaved people were found 
to have positive metacognitive beliefs that rumination/
worry (repetitive negative thinking) was a useful means 
to ‘make sense’ of the death, cope or find answers; nega-
tive metacognitive beliefs that grief-related thoughts 
were uncontrollable or harmful and positive metacog-
nitive beliefs about avoidance (eg, the need to push 
specific thoughts away). Grief-specific metacognitive 
beliefs were also identified, such as the importance of 
using rumination to preserve memories of the deceased; 
emotional regulation as a means to manage grief and 
show respect/love; avoidance behaviours to evade the 
reality of the loss and the use of symbolic objects/rituals 
to maintain a connection with the deceased. Metacog-
nitive beliefs may keep bereaved people focused on loss 
issues, which prevent them from integrating the loss 
into their lives and planning for the future. The findings 
from the study exemplified the need for the develop-
ment of PGD treatments targeting the metacognitions 
that drive unhelpful coping processes.
The Dual Process Model of Coping with Bereavement 
proposes that pathological grief occurs when exclusive 
focus is on either the loss or restoration (eg, secondary 
stressors resulting from the death such as financial 
stressors, employment and child care).19 Therefore, treat-
ment for PGD may be more effective if the focus is shifted 
away from the content of thoughts and toward the modi-
fication of unhelpful metacognitive beliefs about coping 
processes that impede the integration of the loss into 
their lives. Thus, the aim of this pilot study was to explore 
the efficacy and feasibility of a group Metacognitive Grief 
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Therapy (MCGT) for PGD via a preliminary randomised 
controlled trial.
HypOtHeses
1. The intervention group will report significantly greater 
prepost decreases in PGD symptomatology, unhelpful 
metacognitions, rumination, depression, anxiety and 
stress, and a significantly greater increase in quality of 
life, compared with the wait-list (WL) group.
2. For the intervention group, postintervention levels 
in PGD symptomatology, unhelpful metacognitions, 
rumination, depression, anxiety, stress and quality of 
life will be maintained at the 3-month and 6-month 
follow-up.
MetHOD
trial design
The trial comprised a randomised treatment MCGT/
WL control group design with a 3-month and 6-month 
Figure 1 Consolidated Standards of Reporting Trials flow chart of participants through the study. MCGT, Metacognitive Grief 
Therapy; PG-13, Prolonged Grief Disorder Scale.
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follow-up31 (figure 1). The WL control group was offered 
MCGT after the post-test assessment, for ethical reasons, to 
limit participant distress. The sample size obtained in this 
study was small (n=22 intent-to-treat/n=18 completers). 
However, small samples including a WL control group are 
considered sufficient for a pilot trial.32
patient and public involvement
Bereavement guidelines and empirical research with 
bereaved carers clearly point to the necessity of interven-
tions for PGD.4 33 Bereaved adults experiencing prolonged 
grief symptomatology were the target participants for this 
project. Interviews were conducted with key stakeholders 
(bereavement specialists and bereaved people) to ensure 
that the intervention was appropriate, applicable and 
feasible, and to get input from the target population 
directly. The data gleaned from the interviews informed 
the development of MCGT and the project design and 
aims. Although participants in the trial were not involved 
in the recruitment for the study, they assessed the appro-
priateness and acceptability of MCGT. All participants 
received a summary of the project outcomes.
participants
Adult bereaved individuals (age range 38–78 years) at 
least 6 months post the loss of a significant other. Inclu-
sion criteria: prolonged grief symptomatology (PGD 
Scale cut-off score of ≥26, based on previous prevalence 
rates)3 34 or functional impairment (4/5 criteria; A, B, 
C and E), so that people with elevated or diagnosable 
levels of PGD could participate (10 people met PGD diag-
nosis with scores ranging from 38 to 52, 11 people met 
the cut-off score with scores ranging from 27 to 37 and 
1 met criteria A, B, C and E with a score of 23); English 
speaking; written informed consent; participants taking 
medication (antidepressants/mood stabilisers), need to 
have commenced 1 month prior to enrolment and the 
dosage remain the same during the research. Participant 
exclusion criteria: concurrent psychological intervention, 
substance abuse, high suicidal ideation or pre-existing 
psychotic/bipolar/neurological disorder as measured 
by the Mini International Neuropsychiatric Interview 
(MINI).35
Intervention content and delivery
An outline of the MCGT programme is outlined in table 1 
and described in the published PhD36 and protocol.31 
MCGT was adapted from the MCT techniques used by 
Wells37 for emotional disorders, to ensure it aligned with 
MCT and comprised the elements required to target 
unhelpful metacognitive processes effectively. MCGT also 
incorporated grief specific examples to which bereaved 
people could relate.30 It involves an ATT that aims to 
promote the use of detached mindfulness29 37 to develop 
people’s metacognitive control to disengage from 
emotionally laden thoughts and unhelpful behaviours, 
to build coping strategies and process the loss. Thus, 
it changes the way distressing thoughts are processed 
rather than addressing the content. This bodes well for 
treating grief in a group setting, as individuals with PGD 
have been found to be less satisfied with group partici-
pation due to co-rumination (conversations with others 
about the loss).38 The intervention comprised six, 2-hour 
sessions, 1 day per week. Each session was facilitated by 
the primary researcher and a co-facilitator (both provi-
sionally registered psychologists under supervision) at 
the university psychology clinic or a community centre. 
A catch-up booster session was offered to participants 
who missed a session. No differences were found between 
treatment and treated control participants in session 
attendance (t(20)=0.89, p=0.38). Session attendance for 
treatment completers ranged from five to six sessions with 
73.3% completing all six.
Measures
A demographic information sheet was used to obtain 
information such as postcode, gender, current psycholog-
ical treatment, medical history, nationality, employment 
status, relationship with the deceased and the date and 
cause of death.
Table 1 Outline of ‘metacognitive grief therapy’
Session Content
1 Psychoeducation on grief/prolonged grief
Formulate metacognitive model of grief
Enhance awareness of metacognitive beliefs 
involved in grief
Introduce the importance of self-monitoring 
grief-related metacognitive beliefs
2 Explore the link between metacognitions, 
emotions and behaviour
Identify and challenge unhelpful grief-related 
metacognitive beliefs
Introduce and practice detached mindfulness
Introduce rumination/worry postponement
3 Detached mindfulness practice
Introduce and practice attention training
Challenge positive metacognitive beliefs about 
rumination/worry
4 Practice attention training
Challenge negative metacognitive beliefs 
about grief-related thoughts/emotions/images 
being uncontrollable and positive beliefs about 
rumination
Explore metacognitive beliefs underlying the 
need to avoid the reality of the loss
Introduce situational attentional refocusing
Challenge unhelpful metacognitive beliefs about 
avoiding social and leisure activities
5 Practice attention training
Programme review
Maintenance planning
6 Practice attention training
Relapse prevention
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Diagnostic interview
MINI35 was used to identify comorbid disorders and assess 
suicidal risk and ideation. It involves a short structured 
interview based on the DSM-5 Axis I or ICD-10 criteria 
and high test–retest reliability (0.76–0.93) and validity39 
have been reported.
Self-report measures
The PGD Scale (PG-13)3 was used as the primary measure 
to assess the diagnostic status and severity of PGD. 
Diagnosis requires endorsement of five criteria: (A) 
bereavement via the death of a significant other, (B) sepa-
ration distress, (C) duration ≥6 months, (D) cognitive, 
emotional and behavioural symptoms and (E) social/
functional impairment. The 13-item scale requires a yes/
no response for two questions and uses a 5-point Likert 
scale (1=not at all to 5=several times a day/overwhelm-
ingly) to assess symptom severity. A total score is achieved 
by summing the scores (range 11–55). Inclusion in this 
study allowed for subclinical levels of PGD (eg, ≥26 cut-off 
or criteria A, B, C and E) as it is best to have as many 
participants as feasible when testing the efficacy of a new 
intervention within a homogenous sample.32 The PG-13 
has good internal consistency (Cronbach’s α=0.82) and 
incremental validity.40 Internal consistency for PG-13 in 
the current sample was good (α=0.80).
The Depression Anxiety Stress Scales-21 (DASS-21)41 assesses 
depression, anxiety and stress and has high internal 
consistency for depression (α=0.94), anxiety (α=0.87) 
and stress (α=0.91) scales and validity.41 In this sample, it 
had a high internal consistency for depression (α=0.88), 
anxiety (α=0.87) and stress (α=0.88).
The Utrecht Grief Rumination Scale (UGRS)42 measures 
grief-specific rumination. It has five subscales: thoughts 
about consequences and meaning of the loss; thoughts 
about social support; what-if questions; why questions and 
thoughts about feelings. A total score can be obtained 
by summing the subscales (range 15–75). The internal 
consistency (α=0.90) and validity42 of this measure have 
been shown to be excellent. In this sample, the internal 
consistency of the total UGRS was high (α=0.89).
The Metacognitions Questionnaire-30 (MCQ-30)43 was used 
to measure metacognitive beliefs. It has five subscales: 
positive beliefs about worry, negative beliefs about worry 
concerning uncontrollability and danger, low cogni-
tive confidence, need to control thoughts and cognitive 
self-consciousness. A total score is achieved by summing 
the subscales (range 30–120). Internal consistency ranges 
from 0.72 to 0.93 across the subscales with a total internal 
consistency of 0.93 and a test–retest reliability of 0.75.43 In 
this sample, the internal consistency ranged from 0.76 to 
0.98 with a total internal consistency of 0.95.
The Quality of Life Enjoyment and Satisfaction Question-
naire–18 (Q-LES-Q-18)44 assesses general quality of life 
across the following domains: physical health, subjective 
feelings, leisure time activity, social relationships and satis-
faction with medication. A total score can be obtained by 
summing the subscales (range 1–5). It has high internal 
consistency ranging from 0.82 to 0.94 and test–retest reli-
ability ranging from 0.71 to 0.83.44 In the current study, it 
had a high internal consistency of 0.89 and the subscales 
ranged from 0.71 to 0.89.
Therapist measure
The Clinical Global Impression (CGI)45 severity and improve-
ment scales were used to rate each participant’s pretreat-
ment to post-treatment progress. A global rating of severity 
in clinical disorders is determined by scores ranging from 
1 to 7 (normal to among the most extremely ill) and an 
improvement is determined by scores ranging from 1 to 
7 (very much improved to very much worse). A rating of 
1, 2 or 3 (very much improved, much improved or mini-
mally improved) indicates response to treatment. It has 
high inter-rater reliability (0.87 to 0.99). The first author 
and an experienced psychologist (blind to the study) 
independently completed the scale to limit experimenter 
effects. The intraclass correlation (ICC), used to assess the 
inter-rater reliability using the ‘two-way mixed model’ in 
conjunction with the ‘consistency procedure’,46 revealed 
the raters agreed 98% of the time (95% CI 0.97 to 0.99).
procedure
The participants were recruited through advertisements 
on the radio/television and in print media/websites/
flyers in shopping centres, bereavement groups, palliative 
care services and mental health providers. Participants 
who expressed an interest in the study were screened by 
telephone and then attended an individual session to 
complete the MINI. The baseline diagnoses were deter-
mined by the interviewer (first author) prior to scoring 
the self-reported measures to ensure they were blind 
to participant diagnoses. Supervision with an experi-
enced clinical psychologist (fourth author) confirmed 
the accuracy of the diagnoses. Eligible participants were 
randomised prior to assessment by the first author to 
an intervention or WL control condition using a simple 
randomisation procedure (computer-generated random 
number) to avoid research bias in allocation. Randomi-
sation was created using Excel 2013 with 1:1 allocation.
The primary and secondary self-report measures 
were completed by the intervention group at baseline, 
immediately following the intervention and at 3-month 
and 6-month follow-ups. The WL group completed the 
measures at baseline, after a 6-week wait, at treatment 
completion and at 3-month and 6-month follow-ups. All 
interviews and assessments were administered by the first 
author, under the supervision of a clinical psychologist 
(from 2014 to mid-2015). To maintain confidentiality 
and preserve anonymity, an ID number was used to code 
the participants’ data. The data were securely stored in 
a password-protected file on the university server that 
could only be accessed by the research team. Identifying 
information (ie, demographic information and consent 
forms) was kept in a locked filing cabinet in a secured 
university office. Participants were compensated for their 
time at the post-test and 6-month assessment points with 
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a small monetary gift voucher. Participants wishing to 
drop out of the study were provided appropriate referral 
information.
programme integrity and content compliance
A clinical psychologist with extensive MCT experience 
(fourth author) trained and supervised the group facil-
itators (provisionally registered psychologists) and 
confirmed that the integrity of the draft protocol for the 
workshops. To assess the integrity of the detailed session-
by-session manualised MCGT programme delivery and 
to control for protocol adherence, an implementation 
efficacy checklist was completed independently by the 
group facilitator and the co-facilitator at completion of 
each session. The checklist assessed the overall success of 
the session, preparation (knowledge of materials, organ-
isation), presentation (clarity, pacing, thoroughness) 
and rapport using a 10-point Likert scale (1=very poor to 
10=excellent). The ICC46 indicated that the inter-rater 
reliability on the implementation efficacy checklist was 
79% (95% CI, 0.66 to 0.87). The fourth author, with over 
a decade of experience in the delivery of MCT, reviewed 
the session recordings and confirmed adherence to the 
treatment protocol.
social validity/feasibility
The social validity of the programme was measured using 
a programme satisfaction questionnaire. Participants 
rated the overall programme (section A); the practicality 
of the skills taught (section B) and provided qualitative 
feedback (section C). Sections A and B items were rated 
on a 5-point Likert scale ranging from 1 (not at all) to 5 
(very much) and section C comprised five open-ended 
questions for qualitative feedback about the components 
most and least enjoyed. The appropriateness and accept-
ability of the programme was determined by the question-
naire. Descriptive statistics were used to summarise the 
quantitative and qualitative responses.
Data analysis
The independent variables were group condition (MCGT; 
WL) and time. The dependent variable was treatment 
response, measured by change in scores for PGD symp-
tomatology, depression, anxiety, stress, metacognitions, 
rumination and quality of life. A Generalised Linear 
Mixed Model (GLMM) was used to test H1 and H2. The 
model included one categorical random effect (partici-
pant), one categorical fixed effect (group: intervention, 
control), one ordinal fixed effect (time: pretest, post-test) 
and the group×time interaction. A second GLMM was 
used to test H3, which included one categorical random 
effect (participant) and one ordinal fixed effect (time: 
pretest, post-test, 3-month and 6-month follow-up). In 
order to optimise the likelihood of convergence, a sepa-
rate GLMM analysis was run for each of the outcome 
measures (PG-13, DASS-21, MCQ-30, Q-LES-Q-18, 
UGRS). To conserve statistical power, the alpha correc-
tion was applied within groups of conceptually related 
outcomes. The GLMM ‘robust statistics’ option was 
invoked to accommodate any violations of normality and 
homogeneity of variance. Violations of sphericity were 
accommodated by changing the covariance matrix from 
the default of compound symmetry to autoregressive.
Participants were considered to have dropped out 
if they missed more than two treatment sessions. To 
determine whether dropouts differed from completers, 
demographics and baseline outcome measures were 
compared and any between-group differences identi-
fied were controlled by including them as covariates in 
the GLMM. Partial eta-squared and Cohen’s d were used 
to assess treatment effect sizes.47 A reliable change (RC) 
score was calculated for each participant. The RC score 
can be interpreted as the degree to which the partici-
pant changes on the outcome variable divided by the SE 
of difference between the time 1 and time 2 scores. An 
absolute value of the RC score >1.96 reflects an RC.48 For 
participants who demonstrated an RC and their post-test 
score fell below the clinical cut-off, this participant expe-
rienced clinically significant change.48
results
sample characteristics and baseline differences
Of the 53 individuals who expressed interest, 22 (male 
n=1 and female n=21) were eligible and randomised as 
outlined in CONSORT flow chart in figure 1. Indepen-
dent-sample t-tests and Fisher's exact tests revealed no 
significant baseline differences between groups on demo-
graphic and clinical profile characteristics (table 2). Four 
MCGT groups were conducted: group 1=N7, of these one 
participant dropped out due to another participant’s grief 
and completed MCGT individually; group 2=N4, of these 
one participant dropped out due to another participant’s 
grief; group 3=N4, of these one participant dropped out 
due to a family crisis and another was too distressed to 
be with others and completed MCGT individually and 
group 4=N4. There was no significant difference between 
the baseline scores for the treatment and WL group on 
the outcome measures, except on physical health (Q-LES-
Q-18 subscale) t(36)=3.29, p=0.002, with the MCGT group 
exhibiting poorer physical health than the control group. 
No significant difference was found between the baseline 
scores for participants taking medication compared with 
not taking medication (all t(20)<1.89, p>0.31).
treatment effects on primary outcome
Large and significant group×time interactions (table 3) 
were found for PGD severity. MCGT resulted in signifi-
cant prepost reductions on the severity of PGD symp-
tomatology. In contrast, the control group was found to 
significantly increase in PGD severity (PG-13; t(36)=2.06, 
p=0.05, d=0.48). At treatment completion, no MCGT 
participants met the full diagnostic criteria required for 
PGD diagnosis, while in the control group this number 
increased from four to five participants.
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Table 2 Demographic and clinical characteristics of intention-to-treat sample
Characteristic
Treatment Control Total
Significance (n=12) (n=10) (n=22)
Range, mean (SD) Range, mean (SD) Mean (SD) t(20) P values
Age 41–78, 61 (12.3) 38–75, 62 (10.4) 62 (11.2) 0.23 0.82
Time (months) post death 11–72, 29 (18.8) 6–60, 19 (18.5) 24 (18.4) 1.37 0.19
n (%) n (%) N (%) Fisher’s exact p
Relationship to deceased
  Partner 8 (67) 10 (100) 18 (82) 0.07
  Parent 3 (25) 0 3 (14) 0.14
  Child 1 (8) 0 1 (5) 0.55
Employment status
  Employed 3 (25) 2 (20) 5 (23) 0.59
  Self-funded retiree 2 (17) 1 (10) 3 (14) 0.57
  Pension 7 (58) 7 (70) 14 (64) 0.45
Living situation
  Living alone 5 (42) 7 (70) 12 (55) 0.19
  Cohabitating 7 (58) 3 (30) 10 (46) 0.19
Death type
  Sudden 3 (25) 4 (40) 7 (32) 0.38
  Chronic illness 7 (58) 6 (60) 13 (59) 0.64
  Accident 2 (17) 0 2 (9) 0.29
Clinical profile
PGD 6 (50) 4 (40) 10 (46) 0.49
MINI
  Depression 8 (67) 3 (30) 11 (50) 0.1
  Anxiety disorder 9 (75) 5 (50) 14 (64) 0.22
  Post-traumatic stress disorder 1 (8.3) 1 (10) 2 (9) 0.71
Data are expressed as range, means (SD) or as number (rounded %).
MINI, Mini International Neuropsychiatric Interview; PGD, prolonged grief disorder.
Table 3 Outcome variable means (SD) and within-group effect sizes at baseline and post-treatment/postwait-list for the 
intervention and control conditions (intention-to-treat analyses)
Measure
Group
×time
Partial η2
Intervention condition Control condition
F(1, 36) P values Baseline
Post-
treatment
Cohen’s 
d Baseline Postwait-list
Cohen’s 
d
PG-13 28.19 <0.001* 0.44 40.00 (7.03) 26.36 (9.08) 1.68 36.80 (7.34) 40.40 (7.81) −0.48
Depression 14.75 <0.001* 0.29 21.17 (9.39) 9.86 (8.21) 1.28 18.80 (9.93) 24.43 (11.26) −0.53
Anxiety 10.56 0.003* 0.23 16.00 (10.81) 8.20 (9.46) 0.77 12.40 (10.91) 18.36 (13.06) −0.5
Stress 15.20 <0.001* 0.3 20.50 (10.46) 11.19 (7.27) 1.03 16.80 (8.63) 22.13 (11.23) −0.53
MCQ-30 0.83 0.37 0.02 64.00 (18.46) 54.31 (14.69) 0.58 62.70 (20.55) 60.57 (24.25) 0.09
Q-LES-Q-18 6.96 0.01* 0.16 2.96 (0.62) 3.43 (1.00) 0.56 3.29 (0.47) 3.07 (0.70) −0.37
UGRS 6.50 0.02* 0.15 43.67 (10.88) 31.68 (15.14) 0.91 44.60 (14.51) 45.69 (14.55) −0.08
*Denotes a significant difference.
PG-13, Prolonged Grief Disorder Scale; MCQ-30, Metacognitions Questionnaire; Q-LES-Q-18, Quality of Life Enjoyment and 
Satisfaction Questionnaire; UGRS, Utrecht Grief Rumination Scale.
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treatment effects on secondary outcomes
Large significant group×time interactions were found 
for depression, anxiety, stress, rumination (UGRS) and 
quality of life (Q-LES-Q-18; see table 3). Non-significant 
group×time interactions were found for metacognitive 
beliefs (MCQ-30). The least significant difference (LSD) 
contrasts showed that group MCGT resulted in signif-
icant prepost reductions on measures of depression, 
anxiety, stress, rumination and quality of life. In contrast, 
the control group had a significant increase in anxiety 
(t(36)=2.67, p=0.01, d=0.50), stress (t(36)=2.43, p=0.02, 
d=0.53) and a significant decrease in physical health 
(Q-LES-Q-18 subscale; t(36)=2.15, p=0.04, d=0.49), but 
no significant changes in depression, metacognitive 
beliefs or rumination.
Maintenance of change at 3-month and 6-month follow-up
As outlined in table 4, non-significant interaction effects 
indicated that the treated controls made comparable 
gains to the treatment group after receiving MCGT 
across pretreatment, post-treatment and follow-up on 
all outcome variables, except on the UGRS. An LSD 
contrast revealed the treatment group had large signif-
icant prepost reductions that were maintained at the 
3-month follow-up with a further significant reduction at 
the 6-month follow-up, while the treated controls showed 
a large significant prepost reduction with a further signif-
icant reduction at the 3-month follow-up that returned to 
post-treatment level at the 6-month follow-up. Therefore, 
the means for the treatment and treated control groups 
were pooled.
The large significant main effects of time found for PGD 
severity, depression, anxiety, stress, metacognitive beliefs, 
rumination and quality of life suggest gains were made 
from MCGT and maintained at the 3-month and 6-month 
follow-ups. The length of pretreatment wait-times did not 
influence treatment outcomes (all r(15)<0.30, p>0.28). 
No significant differences were identified between partic-
ipants taking medication and those not taking medica-
tion on the treatment outcomes (all t(57)<1.96, p>0.06).
reliable change and clinically significant change
Fisher’s exact one-sided tests revealed that a significantly 
greater proportion of MCGT participants (p=0.005) 
showed prepost reliable change in PGD severity (PG-13; 
67%) than the control group (22%). There were no 
longer significant group differences once the control 
group received MCGT (p=0.71), suggesting both groups 
made similar gains following treatment. At the 3-month 
follow-up, 73% of participants experienced a reliable 
change and 53% experienced a clinical significant change 
(PG-13 criterion of <26 cut-off) in PGD severity. At the 
6-month follow-up, 85% experienced a reliable change 
and 62% experienced a clinically significant change.
therapist measure of treated participants’ progress (CGI)
The GLMM non-significant group×time effect (F(3, 
50)=1.43, p=0.24) indicated treatment and treated T
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controls did not differ in their illness severity or recovery. 
There was a significant effect for time (F(3, 54)=155.80, 
p<0.001) for the pooled groups. LSD contrasts revealed 
significant treatment gains were made from prepost 
(t(54)=8.49, p<0.001, d=3.63), pre-3 months (t(54)=12.48, 
p<0.001, d=4.19) and pre-6 months (t(54)=17.88, p<0.001, 
d=5.07). The pretreatment severity of participants’ illness 
ratings ranged from 4–6 (moderately ill to severely ill; 
mean=4.77, SD=0.75, 95% CI 4.39 to 5.14) to 3–1 (mini-
mally to very much improved) at post-test (mean=2.27, 
SD=0.62, 95% CI 1.96 to 2.58), the 3-month follow-up 
(mean=1.77, SD=0.68, 95% CI 1.43 to 2.11) and 6-month 
follow-up (mean=1.35, SD=0.59, 95% CI 1.03 to 1.66).
programme integrity and content compliance
The co-facilitators rated the delivery of the programme 
higher than the facilitator (mean=9.0, SD=0.94, range 
6–10; mean=8.4, SD=0.69, range 6–9). Descriptive statis-
tics indicated that the overall ratings for the success of the 
group was high (mean=8.2, SD=0.90), as were ratings of 
session preparation (mean=8.7, SD=0.65), presentation 
(mean=8.5, SD=0.78) and rapport (mean=9.01, SD=0.55).
social validity/feasibility
A feasibility analysis was conducted on the Programme 
Satisfaction Questionnaire completed by 12 out of the 15 
treatment completers. Participant ratings ranged from 
four to five (agree to very much agree=100%). Descrip-
tive statistics indicated all participants: looked forward to 
the programme each week (mean=4.8, SD=0.45); found 
the sessions easy to understand (mean=4.7, SD=0.49); 
the programme was useful in everyday life (mean=4.8, 
SD=0.39); were satisfied with the content covered 
(mean=4.8, SD=0.39); the programme was effective in 
helping them (mean=4.6, SD=0.52); they noticed posi-
tive changes in their lives (mean=4.5, SD=0.52); overall, 
rating of the programme (mean=4.8, SD=0.39). Positive 
qualitative feedback indicated participants found the 
workshop helpful: "I have skills to help me move forward" 
… "Understanding myself and being able to cope, accept 
and let go of my feelings". Negative feedback suggested 
some participants would have preferred more sessions.
DIsCussIOn
The results of this pilot study provide preliminary evidence 
for the efficacy and feasibility of a metacognitive-based 
group intervention in treating PGD. Participants showed 
significant improvements in PGD symptomatology, 
depression, anxiety, stress, rumination and quality of life 
following MCGT in comparison to participants in the WL 
control condition. In contrast, people in the WL exhib-
ited significantly poorer grief symptomatology, anxiety, 
stress and physical health at post-test, which may have 
contributed to the significant between-group differences 
observed. We cannot offer any concrete explanation as to 
why the WL control group participants deteriorated as we 
did not directly investigate this.
However, significant improvements in prolonged 
grief symptomatology, depression, anxiety, stress, repeti-
tive negative thinking, quality of life and metacognitive 
beliefs were identified in the pooled groups and these 
improvements were found to be maintained or increased 
at follow-up. The large effect sizes observed on the PG-13 
at post-treatment (d=1.68) and the uncontrolled 3-month 
and 6-month follow-up assessments (d=1.89; d=2.00) 
provide evidence supporting the efficacy of the six-session 
MCGT programme. The mean reduction in prolonged 
grief symptomatology by the 6-month follow-up was 42% 
with 85% of participants identified as having a good 
level of functioning and minimal symptoms (on the CGI 
and RC). The participants indicated that they found the 
programme enjoyable, informative and applicable to 
their everyday lives.
A strength of the study was the longitudinal design 
which controlled for effects such as time and individual 
differences, thus providing a clearer picture of the effect 
of MCGT on outcomes over time. The treatment effects 
in this study were achieved within a short period of time 
using a manualised protocol delivered by novice facil-
itators. It is unlikely the large effects observed can be 
attributed to extraneous factors or spontaneous recovery 
due to the stable baselines and various lengthy dura-
tions of PGD observed across the sample prior to the 
intervention.
Unfortunately, the sample size obtained in this study 
was relatively small and comprised predominantly female 
participants grieving the loss of a spouse and, as such, may 
not be representative of all people with PGD. This may be 
due to the homogeneity of the group, the commonly held 
assumption that grief is a normal process that does not 
require intervention49 or because we were drawing from a 
small proportion of a remote population (Perth, Western 
Australia). We could not compare the intervention and 
WL groups at the two follow-up periods because it was not 
deemed ethical to keep bereaved people waiting a long 
period of time for the intervention.
Furthermore, the results may have been influenced 
by the primary researcher who administered the assess-
ments and conducted the therapy. As such, participants 
may have exaggerated treatment gains to please the ther-
apist.50 It is also possible the improvements could be due 
to mere participation in a supportive group rather than 
the intervention itself, as no comparative treatment was 
used. However, it is important to note that PGD symptoms 
have been shown to persist and become chronic over 
time without targeted intervention (as identified in our 
WL group), yet this pattern was not demonstrated at the 
6-month follow-up. The WL control condition were also 
found to make comparable gains after receiving MCGT, 
providing further support for the need for early interven-
tion for people experiencing PGD symptomatology.40
Additionally, there was a lag in improvements on the 
metacognitive belief questionnaire, which may be because 
it was designed primarily to assess metacognitive beliefs 
about worry and, as such, may not have been specific 
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enough to pick up changes in this sample. The develop-
ment and inclusion of a grief-specific metacognitive ques-
tionnaire in future research with a larger sample size may 
be useful. Another explanation for the lack of change 
on the MCQ-30 at post-test could be that the ability to 
identify and challenge grief-related metacognitive beliefs 
may take time to develop. Moreover, MCGT was devised 
and delivered independently of the originators and thus 
it is possible larger outcomes may have been achieved by 
a facilitator with extensive experience in the delivery of 
MCT. Unfortunately, the small sample obtained meant 
that the study was underpowered for the mediation anal-
yses originally planned.31 However, the significant post-
test reductions in rumination, lend support for MCGT to 
target maladaptive metacognitive beliefs effectively.
Despite these limitations, the participants indicated that 
they were very satisfied with the intervention and felt that 
the intervention was helpful in reducing their distress. 
This was confirmed by the results, which indicated that 
MCGT produced statistically significant improvements 
on the key outcome measures. These encouraging results 
support the need for larger randomised studies of the 
effects of MCGT on PGD compared with another treat-
ment condition and a WL control group with a longer 
follow-up period. The study also supports the call for 
treatments to target PGD symptomatology directly and to 
identify the underlying maladaptive coping mechanisms. 
This is important given that many PGD interventions have 
several components and the efficacy of these components 
remains obscure.4 The clinical implications from this 
study are that PGD treatments incorporating techniques 
that target maladaptive metacognitions directly may be 
integral for optimal treatment gains to be achieved for all 
bereaved individuals.
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